---

1. At a Glance

Neogen Chemicals is that chemical stock which investors treat like a Tesla cousin — because hey, it says “lithium” somewhere in the presentation. Market cap ₹3,774 Cr, sales just ₹784 Cr, profits ₹40 Cr… and a valuation of 93x P/E. Basically, this is the Starbucks latte of stocks: overpriced, fancy-sounding, but still just coffee with foam.

---

2. Introduction

Founded in 1991, back when Doordarshan ruled TV, Neogen quietly grew into a niche specialty chemical player. It imports lithium salts, cooks up 246 different compounds, and sells to everyone from pharma giants (Sun Pharma, Divis) to agro-chemical honchos.

Its claim to fame?

• Largest importer of lithium carbonate & hydroxide in India.
• First Indian co. with Mitsubishi JV-backed lithium electrolyte tech.
• R&D-heavy with 93 scientists (11 PhDs — more than some IIT faculties).

Sounds dreamy, right? Except, profits are flatter than a dosa. Capex is guzzling cash, ROE is 5.5%, and promoter holding has slipped from 60% to 51%. Yet, Dalal Street chants: “Lithium hai toh future hai.”

---

3. Business Model (WTF Do They Even Do?)

Neogen runs two segments:

1. Organic Chemicals (84% of revenue): bromine compounds, intermediates, contract manufacturing for pharma/agro.
2. Inorganic Chemicals (16%): lithium-based inorganics for pharma, batteries, construction.

Applications? From medicines to semiconductors, crop protection to flavours. In short: “agar molecule hai, hum bana denge.”

Add-ons:

• BuLi Chem acquisition (FY24) → Only non-China maker of organolithium outside US/EU.
• Neogen Ionics (subsidiary) → Making lithium electrolytes for EV batteries.

So, the pitch is: “From pills to EVs, we got you covered.” The reality: still small fry compared to Deepak Nitrite or Navin Fluorine.

---

4. Financials Overview

Quarterly Results

Metric	Jun 2025	Jun 2024	Mar 2025	YoY %	QoQ %
Revenue	₹187 Cr	₹180 Cr	₹203 Cr	+3.8%	-7.9%
EBITDA	₹32 Cr	₹31 Cr	₹36 Cr	+3.2%	-11.1%
PAT	₹10.3 Cr	₹11 Cr	₹2 Cr	-6.4%	+415%
EPS (₹)	3.89	4.35	0.91	-10.6%	+327%

Commentary: Growth is flatlining, quarterly profits are swinging harder than Sensex on Budget Day.

---

5. Valuation (Fair Value RANGE only)

• P/E Method
  EPS = ₹12.8. Industry P/E ~33.
  FV Range: ₹420 – ₹520.
• EV/EBITDA
  EV ₹4,365 Cr; EBITDA ₹137 Cr → EV/EBITDA 31x.
  Industry ~15x. FV Range: ₹700 – ₹850.
• DCF (optimistic lithium growth)
  Assume 20% CAGR, terminal 8%, discount 12%. FV ≈ ₹900 – ₹1,100.

👉 Consolidated FV Range: ₹450 – ₹1,100 (Educational only). CMP ₹1,430 = “priced like lithium, earning like bromine.”

---

6. What’s Cooking – News, Triggers, Drama

• ₹1,500 Cr Capex Blitz: Dahej expansions, Pakhajan mega-plant, electrolyte trials. Basically, a shopping spree on steroids.
• MUIS Tech (Japan): Exclusive tie-up for lithium electrolytes → if it works, Neogen becomes EV poster boy.
• BuLi Chem acquisition: Rare asset outside China. Gives pharma/agro advantage.
• Funding via NCDs: ₹200 Cr raised at 10.5% coupon → expensive debt, but keeps capex running.